Affinity Asset Advisors, LLC
Reported holdings as of Q2 2026, from 23 quarterly filings.
Holdings
| Security | Ticker | Value | Shares | Weight | Weight change | Held | Change |
|---|---|---|---|---|---|---|---|
| ROIVANT SCIENCES LTD | ROIV | $132.7M | 3,750,000 | +1.99pp | 6q | +33.9%+$33.6M | |
| APOGEE THERAPEUTICS INC | APGE | $131.0M | 987,000 | +0.34pp | 12q | -23.2%-$39.5M | |
| SPYRE THERAPEUTICS INC | SYRE | $113.6M | 1,279,134 | +1.80pp | 12q | HELD | |
| XENON PHARMACEUTICALS INC | XENE | $96.3M | 1,595,000 | -0.68pp | 15q | -4.8%-$4.8M | |
| ERASCA INC | ERAS | $96.2M | 5,250,000 | -0.12pp | 9q | -1.9%-$1.8M | |
| ALKERMES PLC OPT | ALKS | $72.0M | 1,125,000 | +0.79pp | 12q | -16.7%-$14.4M | |
| INSMED INC | INSM | $69.3M | 650,000 | -0.92pp | 9q | +35.4%+$18.1M | |
| MODERNA INC OPT | MRNA | $68.3M | options only | +0.99pp | 2q | OPTIONS | |
| PRAXIS PRECISION MEDICINES I | PRAX | $61.9M | 185,000 | -0.03pp | 3q | +8.8%+$5.0M | |
| ORUKA THERAPEUTICS INC | ORKA | $56.2M | 590,000 | +1.27pp | 8q | +18.1%+$8.6M | |
| ANAPTYSBIO INC | ANAB | $55.8M | 826,109 | -0.17pp | 3q | -12.1%-$7.7M | |
| AVALO THERAPEUTICS INC | AVTX | $53.6M | 2,900,000 | +1.39pp | 10q | +116.3%+$28.8M | |
| CYTOKINETICS INC | CYTK | $46.9M | 550,000 | -0.27pp | 4q | -21.5%-$12.8M | |
| REVOLUTION MEDICINES INC | RVMD | $46.8M | 250,000 | +1.11pp | 4q | +150.0%+$28.1M | |
| ABIVAX SA | ABVX | $44.0M | 330,000 | -0.34pp | 6q | -18.5%-$10.0M | |
| FIRST TRACKS BIOTHERAPEUTICS | TRAX | $40.9M | 2,032,012 | - | new | NEW | |
| DIANTHUS THERAPEUTICS INC | DNTH | $39.0M | 400,000 | +0.03pp | 4q | +14.3%+$4.9M | |
| SUTRO BIOPHARMA INC | STRO | $38.9M | 1,172,487 | +0.38pp | 3q | +9.6%+$3.4M | |
| NUVALENT INC | NUVL | $34.0M | 275,000 | -0.05pp | 12q | -8.3%-$3.1M | |
| TREVI THERAPEUTICS INC | TRVI | $33.6M | 1,800,172 | +0.29pp | 6q | -10.0%-$3.7M | |
| ARK ETF TR OPT | ARKG | $31.5M | options only | - | new | OPTIONS | |
| OVID THERAPEUTICS INC | OVID | $27.3M | 10,144,562 | +0.01pp | 6q | -4.6%-$1.3M | |
| LEXEO THERAPEUTICS INC | LXEO | $27.0M | 5,807,611 | -0.28pp | 6q | +15.0%+$3.5M | |
| CELLDEX THERAPEUTICS INC NEW | CLDX | $26.0M | 700,000 | +0.36pp | 4q | +40.0%+$7.4M | |
| BELITE BIO INC | BLTE | $25.4M | 165,000 | +0.61pp | 3q | +153.8%+$15.4M | |
| ENLIVEN THERAPEUTICS INC | ELVN | $25.4M | 500,000 | -0.04pp | 2q | -14.8%-$4.4M | |
| FORTE BIOSCIENCES INC | FBRX | $24.3M | 1,145,391 | -0.25pp | 3q | +13.2%+$2.8M | |
| ELI LILLY & CO OPT | LLY | $24.0M | options only | - | new | OPTIONS | |
| NURIX THERAPEUTICS INC | NRIX | $23.5M | 967,620 | +0.29pp | 15q | HELD | |
| ALTO NEUROSCIENCE INC | ANRO | $22.4M | 850,000 | +0.43pp | 2q | +70.0%+$9.2M | |
| MADRIGAL PHARMACEUTICALS INC | MDGL | $21.5M | 40,000 | -0.52pp | 19q | -27.3%-$8.1M | |
| PROTAGONIST THERAPEUTICS INC | PTGX | $21.1M | 172,125 | +0.02pp | 7q | HELD | |
| MINERALYS THERAPEUTICS INC | MLYS | $20.2M | 750,000 | -0.13pp | 10q | HELD | |
| RELAY THERAPEUTICS INC | RLAY | $19.6M | 1,050,000 | +0.68pp | 2q | +162.5%+$12.2M | |
| SAGIMET BIOSCIENCES INC | SGMT | $19.3M | 2,497,864 | +0.64pp | 4q | +187.8%+$12.6M | |
| JADE BIOSCIENCES INC | JBIO | $18.7M | 840,350 | +0.38pp | 5q | +31.3%+$4.5M | |
| COGENT BIOSCIENCES INC | COGT | $17.4M | 450,000 | -0.70pp | 3q | -40.0%-$11.6M | |
| UNIQURE NV OPT | QURE | $17.3M | 175,000 | +0.53pp | 6q | HELD | |
| TRAVERE THERAPEUTICS INC | TVTX | $17.0M | 300,000 | +0.31pp | 7q | HELD | |
| CULLINAN THERAPEUTICS INC | CGEM | $15.9M | 875,760 | +0.15pp | 11q | +12.1%+$1.7M | |
| SAVARA INC | SVRA | $15.5M | 2,512,153 | -0.01pp | 5q | HELD | |
| IDEAYA BIOSCIENCES INC | IDYA | $14.9M | 400,000 | - | new | NEW | |
| PERSPECTIVE THERAPEUTICS INC | CATX | $14.4M | 4,214,582 | -0.03pp | 9q | +33.2%+$3.6M | |
| ODYSSEY THERAPEUTICS INC | ODTX | $14.3M | 766,346 | - | new | NEW | |
| COGENT BIOSCIENCES INC | $13.7M | 11,000,000 | +0.17pp | 3q | DEBT | ||
| OMEROS CORP OPT | OMER | $13.4M | options only | - | new | OPTIONS | |
| HELIX ACQUISITION CORP III | HLXC | $13.3M | 1,250,000 | -0.05pp | 2q | HELD | |
| EQUILLIUM INC | EQ | $13.1M | 4,100,000 | +0.47pp | 2q | +234.3%+$9.2M | |
| ESTABLISHMENT LABS HLDGS INC | ESTA | $12.7M | 148,013 | +0.28pp | 22q | +48.0%+$4.1M | |
| CLIMB BIO INC | CLYM | $12.7M | 972,000 | +0.33pp | 9q | +38.9%+$3.5M | |
| TEVA PHARMACEUTICAL INDS LTD | TEVA | $12.7M | 374,000 | -1.61pp | 13q | -73.3%-$34.8M | |
| VERADERMICS INC | MANE | $12.3M | 100,000 | +0.33pp | 2q | +42.9%+$3.7M | |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | $12.2M | 150,000 | -0.10pp | 3q | -25.0%-$4.1M | |
| OMEROS CORP | $12.2M | 6,525,000 | -0.13pp | 5q | DEBT | ||
| TAYSHA GENE THERAPIES INC | TSHA | $11.9M | 1,750,000 | +0.31pp | 5q | +75.0%+$5.1M | |
| DAMORA THERAPEUTICS INC | DMRA | $11.1M | 425,000 | -0.10pp | 2q | -5.6%-$650.2K | |
| EUPRAXIA PHARMACEUTICALS INC | EPRX | $10.9M | 1,650,000 | -0.10pp | 4q | +3.8%+$403.2K | |
| VERA THERAPEUTICS INC | VERA | $10.7M | 250,000 | -0.03pp | 10q | HELD | |
| PROQR THRAPEUTICS N V | PRQR | $10.3M | 5,543,936 | +0.26pp | 7q | +125.9%+$5.7M | |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | $9.3M | 275,000 | -0.03pp | 13q | HELD | |
| KORRO BIO INC | KRRO | $9.3M | 706,904 | +0.01pp | 2q | HELD | |
| ANTERIS TECHNOLOGIES GLOBAL | AVR | $9.0M | 912,397 | +0.14pp | 7q | HELD | |
| ZURA BIO LTD | ZURA | $8.6M | 1,464,303 | -0.40pp | 10q | -42.9%-$6.5M | |
| ASCENDIS PHARMA A/S | ASND | $8.0M | 30,000 | - | new | NEW | |
| IBIO INC | IBIO | $7.0M | 4,007,881 | +0.01pp | 3q | +29.0%+$1.6M | |
| GENERATE BIOMEDICINES INC | GENB | $6.7M | 400,000 | +0.08pp | 2q | +14.3%+$843.5K | |
| EVOMMUNE INC OPT | EVMN | $6.6M | options only | - | new | OPTIONS | |
| TYRA BIOSCIENCES INC | TYRA | $6.4M | 200,012 | -0.22pp | 2q | -22.3%-$1.8M | |
| SOL-GEL TECHNOLOGIES LTD | SLGL | $6.3M | 84,900 | +0.14pp | 2q | +142.6%+$3.7M | |
| SAB BIOTHERAPEUTICS INC | SABS | $5.9M | 1,525,000 | +0.16pp | 2q | +165.2%+$3.7M | |
| MACROGENICS INC | MGNX | $5.6M | 1,216,606 | +0.18pp | 3q | +143.3%+$3.3M | |
| CRISPR THERAPEUTICS AG | CRSP | $5.5M | 100,000 | -0.12pp | 2q | -33.3%-$2.7M | |
| NEWAMSTERDAM PHARMA COMPANY | NAMSW | $5.3M | 245,000 | -0.01pp | 14q | HELD | |
| ASSEMBLY BIOSCIENCES INC | ASMB | $5.2M | 190,000 | - | new | NEW | |
| REZOLUTE INC | RZLT | $5.2M | 1,000,000 | -0.01pp | 10q | -35.4%-$2.8M | |
| PRECISION BIOSCIENCES INC | DTIL | $5.1M | 646,576 | +0.06pp | 2q | +8.1%+$382.2K | |
| HEMAB THERAPEUTICS HLDGS INC | $5.1M | 138,030 | - | new | NEW | ||
| VIRIDIAN THERAPEUTICS INC | VRDN | $4.6M | 250,000 | -0.04pp | 9q | HELD | |
| ARRIVENT BIOPHARMA INC | AVBP | $4.3M | 125,000 | -0.01pp | 3q | -28.6%-$1.7M | |
| VERRICA PHARMACEUTICALS INC | VRCA | $4.3M | 707,338 | flat | 3q | HELD | |
| COMPASS PATHWAYS PLC | CMPS | $4.3M | 301,183 | -0.12pp | 4q | -72.8%-$11.4M | |
| MBX BIOSCIENCES INC | MBX | $4.1M | 75,000 | -0.04pp | 4q | -50.0%-$4.1M | |
| RESEARCH ALLIANCE CORP III | RACC | $4.0M | 370,000 | - | new | NEW | |
| IMMUNOVANT INC | IMVT | $3.9M | 100,000 | +0.05pp | 4q | HELD | |
| AMANAT ACQUISITION CORP | AMAN | $3.8M | 375,000 | - | new | NEW | |
| BIOHAVEN LTD | BHVN | $3.7M | 250,000 | - | new | NEW | |
| FAETH THERAPEUTICS INC | FTH | $3.6M | 144,404 | - | new | NEW | |
| KARYOPHARM THERAPEUTICS INC | KPTI | $3.1M | 312,500 | -0.01pp | 5q | -37.5%-$1.8M | |
| ALECTOR INC | ALEC | $3.0M | 1,510,000 | +0.08pp | 2q | +202.0%+$2.0M | |
| SPYGLASS PHARMA INC | SGP | $2.9M | 131,586 | -0.20pp | 2q | -47.4%-$2.6M | |
| CRINETICS PHARMACEUTICALS IN | CRNX | $2.8M | 75,000 | -0.01pp | 12q | HELD | |
| OAKTREE ACQUISITION CORP III | OACCU | $2.8M | 250,000 | -0.01pp | 7q | HELD | |
| CELCUITY INC | $2.3M | 2,000,000 | - | new | DEBT | ||
| JATT II ACQUISITION CORP | $2.3M | 200,000 | - | new | NEW | ||
| NEUMORA THERAPEUTICS INC. | NMRA | $1.8M | 1,070,651 | - | new | NEW | |
| AMYLYX PHARMACEUTICALS INC | AMLX | $1.8M | 98,999 | - | new | NEW | |
| ADLAI NORTYE LTD | ANL | $1.8M | 153,847 | +0.02pp | 2q | -6.6%-$125.4K | |
| SPRUCE BIOSCIENCES INC | SPRB | $1.6M | 30,000 | - | new | NEW | |
| SUMMIT THERAPEUTICS INC OPT | SMMT | $1.5M | options only | - | new | OPTIONS | |
| EIKON THERAPEUTICS INC | EIKN | $1.3M | 98,001 | - | new | NEW | |
| ONKURE THERAPEUTICS INC | OKUR | $1.1M | 240,963 | flat | 2q | HELD | |
| Engene Therapeutics Inc | ENGN | $1.0M | 600,000 | - | new | NEW | |
| X4 PHARMACEUTICALS INC | XFOR | $677.1K | 145,000 | flat | 3q | HELD | |
| BOUNDLESS BIO INC | BOLD | $625.0K | 250,000 | - | new | NEW | |
| LENZ THERAPEUTICS INC | LENZ | $568.0K | 100,000 | -0.02pp | 3q | HELD | |
| Q32 BIO INC | QTTB | $353.9K | 27,777 | +0.01pp | 10q | HELD | |
| ORCHESTRA BIOMED HLDGS INC | OBIO | $144.1K | 33,400 | -0.08pp | 4q | -91.7%-$1.6M | |
| NEXTCURE INC | NXTC | $67.1K | 41,960 | -0.13pp | 4q | -82.6%-$319.8K | |
| ADAGIO MED HLDGS INC | ADGM | $52.1K | 80,000 | flat | 8q | HELD | |
| ROCKET PHARMACEUTICALS INC | RCKTW | $278 | 75,000 | flat | 14q | HELD |
By sector
Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.
| Sector | Value | Share |
|---|---|---|
| Biotech & Pharma | $2.0B | 90.7% |
| Other sectors | $40.9M | 1.8% |
| Not classified | $164.0M | 7.4% |
Quarter by quarter
| Quarter | Value | Positions | New | Added | Trimmed | Exited | Top 10 | Days to file |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | $2.2B | 110 | 23 | 33 | 28 | 16 | 40.6% | 44 |
| Q1 2026 | $1.9B | 103 | 26 | 31 | 25 | 15 | 41.6% | 44 |
| Q4 2025 | $1.8B | 92 | 26 | 24 | 20 | 27 | 43.2% | 44 |
| Q3 2025 | $1.1B | 93 | 23 | 26 | 18 | 18 | 44.9% | 44 |
| Q2 2025 | $732.2M | 88 | 19 | 19 | 24 | 22 | 47.2% | 44 |
| Q1 2025 | $1.0B | 91 | 26 | 27 | 17 | 18 | 56.8% | 44 |
| Q4 2024 | $746.0M | 83 | 20 | 24 | 20 | 21 | 47.2% | 44 |
| Q3 2024 | $732.8M | 84 | 18 | 23 | 28 | 25 | 44.6% | 44 |
| Q2 2024 | $867.5M | 91 | 28 | 32 | 17 | 26 | 52.0% | 45 |
| Q1 2024 | $807.8M | 89 | 36 | 28 | 15 | 23 | 42.6% | 44 |
| Q4 2023 | $547.5M | 76 | 18 | 21 | 20 | 16 | 46.3% | 44 |
| Q3 2023 | $355.5M | 74 | 27 | 27 | 12 | 17 | 49.9% | 45 |
| Q2 2023 | $286.3M | 64 | 20 | 15 | 16 | 26 | 50.5% | 52 |
| Q1 2023 | $303.0M | 70 | 20 | 26 | 13 | 10 | 47.5% | 45 |
| Q4 2022 | $255.0M | 60 | 25 | 14 | 11 | 21 | 46.4% | 44 |
| Q3 2022 | $358.3M | 56 | 24 | 11 | 10 | 17 | 60.3% | 45 |
| Q2 2022 | $237.2M | 49 | 13 | 13 | 11 | 20 | 60.2% | 43 |
| Q1 2022 | $625.0M | 56 | 21 | 19 | 8 | 19 | 76.6% | 43 |
| Q4 2021 | $275.4M | 54 | 15 | 17 | 10 | 34 | 43.7% | 42 |
| Q3 2021 | $396.0M | 73 | 23 | 26 | 11 | 19 | 59.9% | 43 |
| Q2 2021 | $279.3M | 69 | 18 | 25 | 13 | 19 | 54.0% | 44 |
| Q1 2021 | $294.5M | 70 | 26 | 22 | 10 | 17 | 59.5% | 44 |
| Q4 2020 | $188.7M | 61 | 0 | 0 | 0 | 0 | 55.6% | 43 |
Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.
Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.
Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.